AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04176900 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ecoflex 030
Description: Polymer used for the 3D-printed flexible bolus
Study NCT03346499 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells and IL-2
Description: Natural Killer Cells
Study NCT02050282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplementary NT-proBNP measurement
Description: In patients randomized to the strategy with supplementary measurement of NT-proBNP, a blood sample will be drawn from the peripheral venous catheter that is routinely inserted and analyzed immediately using a COBAS H232 and Roche Diagnostics NT-proBNP assay.
Study NCT02476695 — intervention group
Intervention type: DEVICE
Intervention: FibroTouch Examination
Description: Liver stiffness measurements are performed using FibroTouch and the procedure is non-invasive and painless.
Study NCT02476695 — intervention group
Intervention type: DEVICE
Intervention: FibroScan Examination
Description: Liver stiffness measurements are performed using another transient elastography, FibroScan, and the procedure is non-invasive and painless.
Study NCT02476695 — intervention group
Intervention type: DEVICE
Intervention: Ultrasonic B Examination
Description: The ultrasonic B examination is made at an empty stomach for ≥8h. The inner diameter of liver, spleen, gallbladder, portal vein and splenoportal vein is measured through the ordinary two-dimensional ultrasonic examination. The echo data of liver surface/edge/parenchyma and gallbladder wall is scored to evaluate the severity of fibrosis.
Study NCT02636023 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPhENo-Cardiograph
Description: SPhENo-Cardiograph
Study NCT03895255 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Paraaortic lymph node dissection, IMA high ligation, TME, routine splenic flexure mobilization
Description: Nerve-sparing paraaortic lymph node dissection is performed. The inferior mesenteric artery is divided at 1-2 cm from its origin from the aorta. Nerve-sparing total mesorectal excision is performed. Splenic flexure is mobilized. Side-to-end sigmoido-rectal anastomosis is created.
Study NCT03895255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paraaortic lymph node dissection, IMA low ligation, TME, selective splenic flexure mobilization
Description: Nerve-sparing paraaortic lymph node dissection is performed. Then inferior mesenteric artery is skeletonized down to the origin of left colic artery and divided below it. Nerve-sparing total mesorectal excision is performed. Splenic flexure is mobilized only if sigmoid colon is unsuitable for anastomosis or doesn't reach the rectal stump. Then descending-rectal side-to-end anastomosis is created.
Study NCT02916251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP4207(dasiglucagon) glucagon analogue
Description: Cross-over design with single s.c. administration in euglycemic and hypoglycemic T1D
Study NCT02916251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon (Native glucagon)
Description: Cross-over design with single s.c. administration in euglycemic T1D
Study NCT03090555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Translational manipulation
Description: After the patient receives an interscalene block on the affected side, a physical therapist performs a series of thrust manipulations on the participant's affected shoulder. The participant's identified limitations of physiological and accessory motion revealed during manual examination guided the physical therapist's choice of technique, which primarily consisted of an accessory superior to inferior accessory gliding motion performed in a physiological position of limited motion. Additional gliding manipulations in combined movement positions such as increased flexion or abduction plus internal or external rotation were utilized until full passive physiologic motion was restored.
Study NCT03090555 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: The first clinic treatment session for all study participants included instruction in the home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and manual therapy (MT) by a physical therapist that included all indicated grades of non-thrust manipulation of the joints and soft tissue. The MT intervention was targeted toward any identifiable upper quarter pain or movement impairments. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program.
Study NCT03090555 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: The first clinic treatment session for all study participants included instruction in the home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and manual therapy (MT) by a physical therapist that included all indicated grades of non-thrust manipulation of the joints and soft tissue. The MT intervention was targeted toward any identifiable upper quarter pain or movement impairments. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program.
Study NCT00952887 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACE-031
Description: Either 2 or 3 subcutaneous doses of ACE-031 over a period of one month, or 7 subcutaneous doses of ACE-031 over a period of 3 months.
Study NCT00952887 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Either 2 or 3 subcutaneous doses of placebo over a period of one month, or 7 subcutaneous doses of placebo over a period of 3 months.
Study NCT03419065 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Relaxation Intervention
Description: Relaxing Music combined with Progressive Muscle relaxation and guided imagery
Study NCT04787055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Receiver-in-canal hearing instrument
Description: Receiver-in-canal hearing instrument
Study NCT02349685 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: H. pylori culture and antimicrobial susceptibility test
Description: Antral and body biopsy specimens were evaluated separately. Organisms were identified as H. pylori by Gram staining, colony morphology, and positive oxidase, catalase, and urease reactions. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin (Sigma Chemical Co., St. Louis, Mo.), clarithromycin (Abbott Laboratories, Abbott Park, Ill.), metronidazole (Sigma), tetracycline (Sigma) and moxifloxacin (Sigma) for the H. pylori isolates were examined by use of the serial twofold agar dilution method and the reference of susceptibility testing was according to the recommendations of the Clinical and Laboratory Standards Institute \[amoxicillin (AMC), MIC ≥ 0.5 μg / ml; clarithromycin (CLA), MIC > 1.0 μ g / ml; metronidazole (MET), MIC > 8 μ g / ml; tetracycline (TC), MIC > 4 μ g / ml; and moxifloxacin (MOX), MIC > 1 μ g / ml).
Study NCT00564447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin topical solution given as a single drop in a single eye
Study NCT02349685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14 day PBMT group
Description: Rescue therapy using 14 day PBMT regimen \[Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d\]
Study NCT02349685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14 day MEA group
Description: Rescue therapy using 14 day MEA regimen (PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.)
Study NCT02906267 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diagnostic ultrasonography of gastric volume
Description: Ultrasonic measurement of gastric insufflation during positive pressure ventilation (secondary endpoint) and final gastric volume after positive pressure ventilation (primary endpoint)
Study NCT01816867 — intervention group
Intervention type: DEVICE
Intervention: Intramesh T1 implantation
Study NCT04073485 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Microwave ablation
Description: Ultrasonogram is performed to identify the fibroid or adenomyoma. A trocar needle is placed into the lesion under local anesthesia. The MWA procedure is performed using appropriate microwave power and application time are selected to provide sufficient ablation coverage to the target lesion.
Study NCT01162811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visualization together with structured behavioural attention.
Description: visualization and relaxation exercises together with structured behavioural attention.
Study NCT00708695 — intervention group
Intervention type: BEHAVIORAL
Intervention: Nurse Home Visiting
Description: Visits from nurses from mid-pregnancy to child age 2 years.
Study NCT02807870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate treatment with a initial dosage of 0,3 mg/kg per day (weekly dosage adjustments).
Study NCT02807870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parental training
Description: Weekly parental training conducted by behavioral psychologists.
Study NCT02807870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducational groups for parents
Description: Weekly psychoeducational groups conducted by educators.
Study NCT02807870 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducational groups for parents
Description: Weekly psychoeducational groups conducted by educators.
Study NCT02807870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo pill
Description: Placebo pill during 8 weeks.
Study NCT02807870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Placebo pill during 8 weeks.
Study NCT00959127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-438162 (MEK162), MEK inhibitor; oral
Description: Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
Study NCT00151372 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Adherence Intervention
Description: The care management intervention aims at facilitating adherence to a treatment algorithm based on the Agency for Health Care Policy and Research (AHCPR) guidelines. The investigators hypothesize that this intervention, in comparison to usual care, will increase the prescription of adequate antidepressant treatment by physicians, enhance treatment adherence by patients, and reduce depressive symptoms, suicide ideation, and disability.
Study NCT00151372 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Care
Description: For subjects in the Enhanced Care group, physicians providing aftercare will receive no clinical instructions by the research team, but will be informed in writing of the patients' diagnosis and will be provided with a copy of the Agency for Health Care Policy and Research (AHCPR) guidelines for the treatment of depression in primary care with an addendum updating the tables describing Selective Serotonin Reuptake Inhibitors (SSRI) side effect and dosage profiles. The investigators expect that these physicians will continue to base their practice on clinical judgment about how best to treat depression in chronic obstructive pulmonary disease patients.
Study NCT00960479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)
Study NCT00960479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)
Study NCT01912339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rezum System
Description: The Rezūm System uses sterile water vapor (steam) to treat BPH by delivering targeted, controlled doses of stored thermal energy directly to the transition zone of the prostate gland.~A narrow sheath, similar in shape and size to a cystoscope, is inserted transurethrally and positioned within the prostatic urethra between the bladder neck and the verumontanum.~A thin needle is deployed through the urethra into the transition zone, and a very short (8-10 second) treatment of water vapor is delivered directly into the hyperplastic tissue and immediately disperses through the tissue interstices.~Upon contact with the tissue, the vapor condenses, or phase shifts, into its liquid state, releasing the stored thermal energy contained within the vapor. This thermal energy is released directly against the walls of the tissue cells within the treatment zone, gently and immediately denaturing the cell membranes, thereby causing instantaneous cell death.
Study NCT01912339 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rigid Cystoscopy
Description: Endoscopy of the urinary bladder via the urethra.
Study NCT01773304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary meal intervention
Description: Test meals with different protein types (dairy versus meat)
Study NCT00528801 — intervention group
Intervention type: BEHAVIORAL
Intervention: NP Battery
Description: Neuropsych Battery with 7 different tests that evaluate the patients neurological functioning.
Study NCT00528801 — intervention group
Intervention type: PROCEDURE
Intervention: MRI
Description: The MRI is a standard procedure involving 30 minutes under the machine in order to obtain various images of the patients brain.
Study NCT03721497 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Testosterone Undecanoate
Description: The patients will be randomly assigned to either testosterone or placebo.
Study NCT03721497 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Undecanoate
Description: The patients will be randomly assigned to either testosterone or placebo.
Study NCT00679172 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose of 5.0 x 10^9 CFU (Cohort 1)
Description: S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
Study NCT00679172 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose of 7.5 x 10^9 CFU (Cohort 2)
Description: S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
Study NCT00679172 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose of 1.1 x 10^10 CFU (Cohort 3)
Description: S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
Study NCT00679172 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dose of of 1.7 x 10^10 CFU (Cohort 4)
Description: S. typhi (Ty2 aroC-ssaV-) ZH9 live attenuated typhoid vaccine, single dose, oral administration
Study NCT00679172 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo (Cohorts 1-4 pooled)
Description: Excipients only, single dose, oral administration
Study NCT01910467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS visible and predefined interventions
Description: NIRS measurements are visible and the patients will be treated according to predefined clinical interventions: If cTOI/pTOI ratio increases >5% within a six-hours-period echocardiography will be performed and based on results of echocardiography and blood pressure a volume bolus or, if ventilated, modification of ventilation or treatment of patent ductus arteriosus will be considered.
Study NCT01910467 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NIRS not visible and treatment as usual
Description: NIRS not visible and the patients will be treated according to routine
Study NCT04359979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: selective alpha1 receptor antagonist
Study NCT01058629 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SynergEyes A2 Hybrid Contact Lens
Description: SynergEyes A2 is a hybrid contact lens cleared by the US Food and Drug Administration (FDA) for daily wear correction of up to +20.00 and -20.00 in eyes with astigmatism up to 6.00D and for presbyopia.
Study NCT03720288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.
Study NCT03720288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patient will follow the treatment according to inclusion sequence, receiving the corresponding number medication.
Study NCT04438291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MDL-SHPVP
Description: A 2-hour education session with multicomponent interventions including education sessions with small group dialogues with a registered nurse and trained healthcare and lay volunteers and educational computer games
Study NCT04438291 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 30-minute educational video
Description: A 30-minute education video (DVD) on HPV, cervical cancer and the HPV vaccine that is designed to enhance HPV vaccine acceptance
Study NCT02408523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide Tablet
Description: * Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated Tablet~* Concentration: 50 mg~* Route of Administration: Oral use
Study NCT03907488 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan
Study NCT03907488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03907488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03907488 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Receive radiation therapy
Study NCT03907488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine Sulfate
Description: Given IV
Study NCT02497911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine
Study NCT04306211 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SuperNO2VA
Description: SUPERNO2VA is nasal PAP device for oxygen delivery
Study NCT03161665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMT Roadmap
Description: The BMT Roadmap is a health IT System that has been developed for use on the Apple iPad® to give the patient and caregivers easy access to test results, current treatment and contact information to hopefully increase active participation and engagement in transplant care.
Study NCT01070199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: liquid to liquid
Description: • One test session will involve presentation of a glass of clear cherry-flavored unthickened beverage (Kool-Aid, Kraft Foods Inc., White Plains, NY). This session will be referred to as the Liquid to Liquid session as the participants will be consuming a liquid and be told that the consistency in their stomach will be a liquid.
Study NCT01070199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: liquid to solid
Description: This session involves a solution of calcium chloride and a solution of sodium alginate. The participant will be instructed to pour the cherry-flavored beverage/alginate solution into the calcium chloride. The result is a solid mass. They are allowed to examine the solution to confirm the solid texture and consistency.Participants will be told that this same reaction will occur in their stomach when the session's beverage is consumed due to the effect of gastric acid on the solution. But, the participant will be consuming the same cherry-flavored beverage as in the 1st session. Thus, they will believe that their GI tract will be challenged with a solid mass, but in reality, the challenge is the same (i.e., liquid).Therefore, the only difference between the test sessions is expectation.
Study NCT04306211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SuperNO2VA
Description: SUPERNO2VA is nasal PAP device for oxygen delivery
Study NCT00595309 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IC51
Description: IC51, 6 mcg, intramuscular (i.m.) booster vaccination 15 months after the primary immunization
Study NCT06035835 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Lacticaseibacillus rhamnosus
Description: Administration Lacticaseibacillus rhamnosus (L. Rhamnosus) ATCC 53103 (109 UFC/day)
Study NCT06035835 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Lactobacillus acidophilus + Bifidobacterium bifidum
Description: Administration Lactobacillus acidophilus (L. acidophilus) ATCC 4356 (109 UFC/12 h)+Bifidobacterium bifidum (B. bifidum) ATCC 15696 (109 UFC/12 h)
Study NCT03214783 — intervention group
Intervention type: OTHER
Intervention: Facial characteristics
Description: The exposures are facial characteristics which differ significantly in exposure rates between coronary artery disease (CAD) group and no CAD group.
Study NCT04728009 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Longan and lingzhi mushroom syrup
Description: Fresh fruit pulps of longan were stewed in hot water until they softened. No sugar and additives were added. The pulps were removed by filtration in order to obtain concentrated longan juice. After that, spray-dried powder of lingzhi mushroom extract was dissolved in water in the ratio of 1:2. To make the finished product, 99 g of longan juice was mixed with 1 g of the lingzhi extract in water. The sugar content of the syrup was 77 degrees Brix.
Study NCT03309865 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: semi-vegetarian diet
Description: semi-vegetarian dietary intervention: Duration of Therapy: 14 weeks;
Study NCT03309865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab Injection
Description: vedolizumab (300mg) IV infusions at week 0, 2, 6, 14; Duration of Therapy: 14 weeks